In patients who underwent radical resection for gastric cancer, we investigate the relative efficacy of combined 5-fluorouracil + adriamycin or epirubicin and methotrexate with leucovorin rescue (FAMTX or FEMTX) compared with a control arm.
introduction Surgery remains the primary treatment modality for patients with gastric cancer. In Europe and the United States, the average 5-year survival rate after radical surgery is 30-40%; most patients die from locoregional recurrences and/or distant metastases. In studies in Western countries [1, 2] and in Asia [3] , more than 50% of patients have lymph node metastases at the time of resection, and are therefore at high risk of relapse. For several decades attempts have been made with chemotherapy to improve upon the low rate of cure following surgery in patients with advanced gastric cancer.
In the late 1980s, in a prospective phase III multicentre trial conducted by the EORTC Gastro Intestinal (GI) Group, 213 patients with metastatic gastric cancer were randomized to receive sequential high-dose FAMTX or FAM. FAMTX-treated patients were found to have a significantly greater response rate (41% versus 9%; P < 0.0001) and overall survival than FAM patients (median 42 weeks versus 29 weeks; P = 0.004) [4] . These promising findings prompted the EORTC GI Group to design an adjuvant-randomized clinical trial to investigate the efficacy of FAMTX with leucovorin rescue versus no treatment, which was still considered standard practice for patients with radically resected gastric cancer. At that time, the ICCG was also investigating 5-FU+ epirubicin (E) + MTX with leucovorin rescue (FEMTX) versus surgery only. (ICDM) appointed for both studies recommended that both trials should be closed due to poor accrual and that the data obtained should be considered jointly in a prospective meta-analysis. The results of the analysis of these studies are reported in the present paper.
patients and methods
patients
Inclusion criteria for both trials included: age <71 years; adenocarcinoma of the stomach or esophago-gastric junction treated with curative resection with macroscopically negative resection margins; pathological stage Ib, II, IIIa, IIIB and IV (only M0) according to the UICC staging system (1987); WBC ‡ 4.0 · 10 9 /l; platelets ‡100 · 10 9 /l; adequate renal and hepatic function; plasma albumin ‡35 g/l; no evidence of metastasis; Karnofsky score >70 (i.e. WHO performance status 0-2); patient's condition good enough for chemotherapy to be given within 4 weeks of resection; patient's fully informed consent.
treatment
The surgical procedure recommended for the primary tumour was subtotal gastrectomy, for lower third tumours, and total gastrectomy, for middle and upper tumours. For tumours of the esophago-gastric junction, an esophago-gastric resection was preferred, an abdomino-thoracic route being used whenever possible. D2 lymphadenectomy was required in the EORTC trial. On an 'ad hoc' form, the surgeon specified the anatomical location of the lymph nodes removed. The patients were screened for admission to the study from 10 to 28 days after surgery and, if randomized to the treatment arm, chemotherapy was started within 4 weeks of surgery.
FAMTX 
follow-up
Follow-up controls (performed every 29 days for the first 6 months, every 6 months until the end of the 5th year and yearly thereafter) consisted of a physical examination, complete blood count, liver and renal function tests, plasma-albumin test, chest radiography, liver echography or liver CAT alternately, and barium meal test or gastroscopy alternately. Biopsy of local or distant metastases was performed whenever possible. Typical nodules on liver echography, CAT scan or chest radiography, or lytic areas of damage on skeletal X-ray are acceptable as metastases without histological confirmation if they reflect a definitive change with respect to baseline studies.
statistical considerations
For the EORTC trial, randomization was achieved by minimization with stratification according to institution, pathological stage (IB versus II versus IIIA versus IIIB) and tumour location (esophago-gastric junction versus stomach); at ICCG trial, patients were randomized according to permuted blocks within strata defined by institution and pathological stage (IB/II versus IIIA/IIIB/IV).
In both the multicentre trials, the primary endpoint was OS. Secondary endpoints were treatment toxicity and DFS. OS was defined as the interval from the date of randomization to the date of death. DFS was the interval from the date of randomization to the date of recurrence or death, whichever occurred first.
The ICCG trial was designed to detect a 15% improvement in 5-year OS (from 45 to 60%) at a 5% two-sided significance level with 90% power. The original sample size planned was 480 (230 patients per arm plus dropouts), in order to observe the 218 events (deaths) required to test the hypothesis.
The EORTC trial was designed to detect a 10% improvement in 3-year OS (from 50 to 60%) at a 5% two-sided significance level with 80% power. The original sample size planned was 760 (380 patients per arm) in order to observe the 344 deaths required to test the hypothesis.
Both OS and DFS were estimated using the Kaplan-Meier method. Considering both trials together, the treatments were compared for these endpoints by means of the log-rank test, and retrospectively stratified by trial. Analysis used the intent to treat principle, i.e. all randomized patients were included and analysed in the treatment group assigned at randomization. Formal statistical tests were not performed separately for each trial due to the lack of power in both the studies.
Independent Data Monitoring Committee (IDMC)
Due to the low accrual in both trials, after 7 years of recruitment a common IDMC was convened to review these studies. The trials were considered sufficiently similar to be pooled for analysis. In June 1996, based on a joint analysis of the ICCG and EORTC trials, the IDMC advised the investigators to increase the accrual rate of the studies. However, during the subsequent 18 months, only 65 further patients were randomized. On meeting again in March 1998, the IDMC concluded that patient accrual had declined to such a point that both trials should be closed.
Given the objectives and hypotheses in both trials, and considering the longer follow-up period required for the patients already randomized, it was decided that, combined, these studies could still provide valuable findings. The IDMC therefore recommended a joint analysis when a total of 218 deaths were reported across both trials.
results patient accrual and characteristics
From July 1990 to March 1998, a total of 397 patients were randomized: 191 by 16 ICCG institutions and 206 by 23 EORTC institutions (the FAMTX trial opened in February 1991). Eight patients were ineligible (inadequate surgery, 1; locally advanced disease, 2; metastatic disease, 5). The numbers of patients randomized for each trial are reported in Figure 1 . Table 1 reports the age, sex and primary tumour sites. The types of surgical procedure performed are shown in Table 2 . There were important differences between the two trials for extent of surgery. In the EORTC trial, in which a D2 dissection was recommended, 87% of patients underwent this procedure. The median number of lymph nodes removed was 13 in the ICCG, and 20 in the EORTC trial. Tumour characteristics were similar in both trials, but the ICCG study included a greater number of patients with infiltrated resection margins and patients with advanced (stage IV) disease (Table 3) . Within each trial, patient characteristics, surgery type and pathology data were well balanced across the two treatment groups. Table 4 shows the number of chemotherapy cycles administered.
FAMTX. Eight (8%) of 103 patients randomized to chemotherapy received no treatment. Five patients refused, one had postoperative complications, one was erroneously considered as randomized in the control arm; for another patient, no reason was given for this omission. Of the 103 patients, 76 (74%) received the six planned cycles of treatment.
One patient randomized to the control arm was considered randomized to the treatment arm and received four cycles of FAMTX.
FEMTX. Ten (11%) of 91 patients randomized to chemotherapy did not start treatment. Three refused treatment, one was treated as a control, three had distant metastases discovered after randomization, one patient had a second primary tumour found after randomization and two patients preferred to undergo alternative chemotherapy. In a further two cases, no data were available. Of the 91 patients, 55 (60%) received the six cycles of treatment. (24) 26 (25) 23 (23) 
Tumour stage T1 10 (10) 7 (7) 4 (4) Table 5 shows the rate of grade 3-4 toxicity, which was mainly haematological. In each trial there were two deaths from toxicity. The causes of death from toxicity were: renal failure and sepsis (one patient), sepsis (one patient) in the FAMTX trial, and cerebral stroke (one patient), renal failure and sepsis (one patient) in the FEMTX trial. FAMTX and FEMTX treatment, respectively, incurred 29% and 52% grade 3 alopecia, 29% and 25% grade 3-4 leucopenia, 32% and 4% grade 3-4 neutropenia and 12% and 14% grade 3-4 nausea and vomiting.
efficacy
In the EORTC trial, with a median follow-up of 6.6 years, 50/103 (49%) of the patients in the control group and 40/103 (39%) in the treated group had local or distant disease recurrence (Table 6 ). At a median follow-up of 6.4 years, the incidence of recurrence in the ICCG trial was 54% in the control group and 50% in the treated group. However, on taking into account both recurrences and deaths, the Kaplan-Meier DFS curves for the EORTC and ICCG trials did not indicate any difference between findings from treated patients and those from controls. In the EORTC trial, the hazards ratio (HR) for DFS was 0.90 [95% confidence interval (CI): 0.54-1.26] with a 5-year DFS of 51% (95% CI: 41-60%) in the FAMTX arm and 50% (95% CI: 40-59%) in the control arm. In the ICCG trial, the HR for DFS was 1.04 (95% CI: 0.68-1.40) with a 5-year DFS of 29% (95% CI: 19-39%) in the FEMTX arm and 34% (95% CI: 24-44%) in the control arm.
On considering first relapse, distant recurrences were found to be more frequent than local recurrences: 69 patients (33%) versus 29 (14%), respectively, in the EORTC study and 96 patients (50%) versus 25 (14%), respectively, in the ICCG study. On considering all patients from both trials, it was found that 14% developed concurrent local and distant progression. Sites of local and distant disease progression are listed in Table 6 .
In the EORTC trial, 49/103 (48%) of control group patients and 54/103 (52%) of FAMTX patients were alive at the time of analysis. In the ICCG trial, 36/100 (36%) control patients and 28/91 (31%) FEMTX patients were alive. Eighty-five per cent of deaths were due to malignant disease.
Kaplan-Meier OS curves for the EORTC and ICCG trials did not show any difference between treated patients and controls. Thrombophlebitis n = 1, cardiac (type not specified) n = 1, myelosupression n = 1, mucositis n = 2, anorexia n = 1, esophagitis n = 1. (87) 37 (76) 58 (91) 53 ( (6) 1 (2) 2 (3) 3 (5) No recurrence 53 (51) 63 (61) 46 (46) 41 (45) Recurrence 50 (49) 40 (39) 54 (54) 50 (55) Local only 12 (24) 7 (18) 3 (6) 5 (10) Local + distant 7 (14) 3 (8) 12 (22) 5 (10) Distant only 30 (61) 29 (74) 39 (72) 40 (80 
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In the EORTC trial, the HR for OS was 0.89 (95% CI: 0.51-1.31) with a 5-year OS of 52% (95% CI: 42-62%) in the FAMTX arm and 51% (95% CI: 41-61%) in the control arm. In the ICCG trial, the HR for OS was 1.05 (95% CI: 0.69-1.41) with a 5-year OS of 33% (95% CI: 23-42%) in the FEMTX arm and 36% (95% CI: 26-45%) in the control arm. Figures 2 and 3 show the results of the combined analysis for OS and DFS, respectively, in all patients from both trials. No significant difference was found between the arms for DFS (HR: 0.98, 95% CI: 0.72-1.24, P = 0.87) and OS (HR: 0.98, 95% CI: 0.72-1.24, P = 0.86). Five-year DFS was 41% (95% CI: 34-48%) in the treatment arm and 42% (95% CI: 35-49%) in the control arm, and 5-year OS was 43% (95% CI: 36-50%) in the treatment arm and 44% (95% CI: 36-51%) in the control arm.
discussion
In the combined analysis of the EORTC FAMTX and ICCG FEMTX trial findings, no significant differences for DFS or OS were found between patients with gastric cancer treated with FAMTX or FEMTX after radical resection and patients who underwent surgery alone. However, even this pooled analysis lacks the statistical power required to detect absolute differences of the order of 10%. The analyses made were based on all randomized patients. Eight patients were not eligible and 14 other patients did not start chemotherapy for various reasons. Six patients, who had been allocated to the control arm, received chemotherapy. This accounted for 7% of all patients (28/397), but a sensitivity analysis carried out excluding these patients did not show changes in the results (data not shown).
Furthermore, 74% of patients enrolled in the EORTC trial, and 60% of those enrolled in the ICCG trial, received all six cycles of treatment. Most patients who discontinued treatment stopped due to toxicity or because they refused to continue for all six cycles. In both trials, grade 3-4 toxicity was reported in 30% of patients, leading to dose reductions in >50% of cases. These results suggest that the toxicity of these regimens should be taken seriously into account in the future. The potential high toxicity incurred by FAMTX/FEMTX treatments was one of the reasons for the slow and declining accrual of patients and the final closure of the studies. Others contributory factors were the complexity of the regimen, and the knowledge that ECF has advantages over FAMTX treatment [5] .
The overall 5-year survival was 43%: 51% in the EORTC trial and 34% in the ICCG trial. An analysis of the surgical procedures used in the two trials showed differences between extent of surgery. In the EORTC trial, which called for D2 dissection, 89% of patients underwent this procedure. The median number of lymph nodes removed was 13 in the ICCG study, whereas in 74% of EORTC trial patients, 13 or more nodes were removed (median number 23 and 18 in control and chemotherapy arms, respectively). Although a formal comparison of the extent of surgery in the separate trials cannot be made, it is tempting to suggest that the more radical surgery performed in the EORTC study may have resulted in a better survival than the less radical surgery performed in the ICCG trial. However, any claims that extended lymphadenectomy (D2) is beneficial are controversial because of findings made in two trials conducted in Europe to compare outcome following D1 and D2 lymphadenectomy [6, 7] . Both studies reported a significant increase in mortality and morbidity rates and longer mean hospital stays following D2 lymphadenectomy, without finding that it provided benefit in terms of overall and disease-free survival. Although these results are not supported by findings made by other institutions in Europe and the USA dedicated to gastric surgery [1, [8] [9] [10] , D1 lymph node dissection is still widely performed in Western countries and it was recently reported that, in the USA, D2 dissection is performed in only 4-7% of cases [11] . Finally, after a prolonged follow-up, the D2 arm of the Dutch randomized study has now shown a trend for overall survival benefit, this difference being significant with respect to the subgroup of N+ patients [12] .
Following 'second-generation' combined chemotherapy regimens (e.g. 5-FU with etoposide or cisplatin) developed in the 1980s with a high activity in locally advanced and metastatic disease [13] , similar regimens have been proposed in the adjuvant setting. A French trial with FUP (infusional 5-FU for 5 days + cisplatin) included 260 eligible patients and reported [14] . An adjuvant chemotherapy trial of EAP (etoposide, adriamycin, cisplatin) versus 5-FU/LV, reported from Italy on 274 patients, was associated with 5-year survival of 52% in the treatment arm and 48% in the control arm (HR: 0.93, 95% CI 0.65-1.34) [15] . In another Italian trial [16] , on 258 patients with stage Ib-IV (M0) gastric cancer, the PELF (cisplatin, epirubicin, leucoverin, 5-FU) regimen reduced the mortality rate by 9%, although this reduction was not significant (HR = 0.91; 95% CI 0.64-1.28). In an Intergroup/SWOG study, radiotherapy plus 5-FU/leucovorin was investigated in patients who underwent resection for gastric cancer [17] . Although chemotherapy plus radiotherapy was followed by a significant survival benefit, 54% of the patients had less than D1 lymphadenectomy and no more than 10% underwent D2 lymphadenectomy; it has been claimed that the poor standard of surgery in this study contributed heavily to the results obtained [11] . In most European series, survival data reported in patients who undergo combined treatment are no better than those in patients who undergo optimal surgery (more than D1 resection) alone.
In the last 10 years, five meta-analyses have evaluated the role of adjuvant chemotherapy for gastric cancer [18] [19] [20] [21] [22] . All suggest that a slight survival benefit is provided by adjuvant chemotherapy, but the findings are mainly generated by a few small studies from Spain [23] while all large multicentre trials conducted have reported no benefit. In these trials, as found in the present study, series have not been large enough to reveal smaller differences, in the order of 5-10%. Findings from larger clinical trials are needed to demonstrate such small differences.
An ongoing Italian clinical trial on sequential treatment with CPT11 + 5FU/LV + taxotere + CDDP versus 5FU/LV regimen plans to enrol 1200 patients in order to verify a minimum progression-free survival advantage (at 3 years) of 5-10%.
Preoperative chemotherapy may be a better approach. Results of the UK 'MAGIC' trial, comparing preoperative and postoperative epirubicin + cisplatin + 5-FU (ECF) with surgery alone, have recently been presented [24] : 5-year survival rates for the perioperative chemotherapy group and the surgery alone group were 36% and 23%, respectively (P = 0.009). Progressionfree survival was also significantly prolonged (P =0.0001). Unfortunately, however, surgery was not well defined. OS in the surgery alone arm was only 23% at 5 years which is inferior to the outcome of European trials discussed above and also to survival in the present study. In 1999, the Swiss Group for Clinical Cancer Research initiated a phase III trial of preoperative versus postoperative chemotherapy with taxotere + cisplatin + 5-FU in patients with locally advanced resectable gastric carcinoma. The outcome from this study is awaited with interest.
In conclusion, no significant benefit has been observed following postoperative second-generation polychemotherapy. There is now a need for findings from new clinical trials using the preoperative or postoperative administration of potentially more effective drugs (irinotecan, taxanes) probably in combination with radiotherapy to be compared with those following optimal surgery alone. This type of study should be performed by inter-group consortium (e.g. PETACC) uniting national groups with a view to accruing a sufficient number of patients. Annals of Oncology original article
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